title: Relations of APOE promoter polymorphisms to LDL cholesterol and markers of subclinical atherosclerosis in young adults.
abstract: The common apolipoprotein E (apoE) gene (APOE) epsilon2/epsilon3/epsilon4 polymorphism explains part of serum lipid variation, and polymorphisms in the APOE promoter region have been proposed to participate in the regulation of serum lipid levels within the most common APOE epsilon3/epsilon3 genotype group. We determined APOE -219G/T and +113G/C promoter genotypes and estimated APOE haplotypes in 525 participants of the Cardiovascular Risk in Young Finns Study. We studied the associations of the APOE promoter polymorphisms and their haplotypes with cross-sectional and longitudinal serum lipid and apolipoprotein concentrations as well as with flow-mediated dilatation (FMD), carotid artery compliance (CAC), and intima-media thickness (IMT) within the APOE epsilon3/epsilon3 carriers. We found no significant association between the APOE promoter genotypes and serum lipids [low density lipoprotein-cholesterol (LDL-C), HDL-C, and triglycerides], apolipoproteins (apoA-I and apoB), or brachial artery FMD, CAC, or carotid IMT in either men or women. In longitudinal analyses in males, the carriers of heterozygous genotypes (-219G/T or +113G/C) and, furthermore, carriers of the -219T/+113C/epsilon3 haplotype had significantly higher LDL-C and total cholesterol concentrations throughout the 21 year follow-up period compared with homozygous G allele carriers or noncarriers of the -219T/+113C/epsilon3 haplotype. Such associations were not found in females. In summary, the APOE promoter polymorphisms -219G/T and +113G/C as well as their haplotype are associated with longitudinal changes in LDL-C and total cholesterol concentrations in young Finnish males but do not seem to be major determinants for FMD, CAC, or carotid IMT in males or females.
authors.affiliation: Department of Forensic Medicine, University of Tampere Medical School, and Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland. leena.viiri@uta.fi
authors.forename: Leena E
authors.initials: LE
authors.lastname: Viiri
authors.forename: Olli T
authors.initials: OT
authors.lastname: Raitakari
authors.forename: Heini
authors.initials: H
authors.lastname: Huhtala
authors.forename: Mika
authors.initials: M
authors.lastname: Kähönen
authors.forename: Riikka
authors.initials: R
authors.lastname: Rontu
authors.forename: Markus
authors.initials: M
authors.lastname: Juonala
authors.forename: Nina
authors.initials: N
authors.lastname: Hutri-Kähönen
authors.forename: Jukka
authors.initials: J
authors.lastname: Marniemi
authors.forename: Jorma S A
authors.initials: JS
authors.lastname: Viikari
authors.forename: Pekka J
authors.initials: PJ
authors.lastname: Karhunen
authors.forename: Terho
authors.initials: T
authors.lastname: Lehtimäki
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001057:Apolipoproteins E / Q000235:genetics*; D050197:Atherosclerosis / Q000097:blood / Q000235:genetics / Q000473:pathology*; D015415:Biomarkers / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008954:Models, Biological; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics*
chemical_list: D001057:Apolipoproteins E; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D002784:Cholesterol